Entering text into the input field will update the search result below

FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q4 2019 Results - Earnings Call Transcript

Mar. 02, 2020 7:38 PM ETFibroGen, Inc. (FGEN) Stock
SA Transcripts profile picture
SA Transcripts

FibroGen, Inc. (NASDAQ:FGEN) Q4 2019 Earnings Conference Call March 2, 2020 5:00 PM ET

Company Participants

Mike Tung - Investor Relations

Enrique Conterno - Chief Executive Officer

Peony Yu - Chief Medical Officer

Chris Chung - Senior Vice President, China Operations

Elias Kouchakji - Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance

Pat Cotroneo - Chief Financial Officer

Conference Call Participants

Michael Yee - Jefferies

Geoffrey Porges - SVB Leerink

Andy Hsieh - William Blair

Joel Beatty - Citi

Paul Choi - Goldman Sachs

Difei Yang - Mizuho Securities


Ladies and gentlemen, thank you for standing by. And welcome to the FibroGen Fourth Quarter and Full Year 2019 Conference Call. At this time, all participant lines are in a listen-only mode. After the speaker’s presentation, there will be question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]

I would now like to hand the conference over to your speaker today, Mike Tung. Thank you. Please go ahead, sir.

Mike Tung

Thank you, Justin, and good afternoon, everyone. Thank you for joining us on today's call to discuss FibroGen's performance for the fourth quarter and full year 2019. Today's call will be led by Enrique Conterno, our Chief Executive Officer; Enrique will be joined by Dr. Peony Yu, our Chief Medical Officer; and Ms. Chris Chung, our Senior Vice President of China Operations; Dr. Elias Kouchakji, our Senior Vice President of Clinical Development, Drug Safety and Pharmacovigilance; and Mr. Pat Cotroneo, our Chief Financial Officer.

Before we begin, I would like to point out that we may make forward-looking statements regarding our business, including our collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct and results of clinical trials; our regulatory strategies and potential regulatory results; our research and development activities; commercial results and results of operations; risks related to our

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About FGEN

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on FGEN

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.